Article Information
History
- July 19, 2024.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Marion Leboyer1,*,
- Marianne Foiselle1,
- Nicolas Tchitchek2,
- Ryad Tamouza1,
- Roberta Lorenzon2,3,
- Jean-Romain Richard1,
- Raphaele Arrouasse4,
- Philippe Le Corvoisier4,
- Katia Le Dudal4,
- Eric Vicaut5,
- Pierre Ellul2,
- Michelle Rosenzwajg2,3 and
- David Klatzmann2,3,*
- 1Université Paris Est Créteil (UPEC), AP-HP, Department of Psychiatry, Hôpital Henri Mondor, DMU IMPACT, FHU ADAPT, INSERM U955, IMRB, Translational NeuroPsychiatry Laboratory, 51 Avenue du Maréchal de Lattre de Tassigny, 94010 Créteil, France
- 2Sorbonne Université, INSERM, UMR_S 959, Immunology-Immunopathology-Immunotherapy (i3); F-75651, Paris, France
- 3AP-HP, Pitié-Salpêtrière Hospital, Biotherapy (CIC-BTi) and Inflammation-Immunopathology-Biotherapy Department (i2B), F-75651, Paris, France
- 4Inserm, Centre d’Investigation Clinique 1430 et AP-HP, Hôpitaux Universitaires Henri Mondor, Univ Paris Est Creteil, F-94010 Créteil, France
- 5AP-HP, Saint Louis/Lariboisière Hospitals, Unité de recherche clinique and Université Paris 7, F-75010, Paris, France
- ↵*Corresponding Authors: Prof. Marion Leboyer, Hôpital Albert Chenevier, department of psychiatry, 40 Avenue de Mesly, Creteil 94000, France, Email: marion.leboyer{at}inserm.fr, Phone: + 33 1 49 81 30 51; Prof. D. Klatzmann, Hôpital Pitié-Salpêtrière, Clinical Investigation Center for Biotherapies and Immunology-Immunopathology-Immunotherapy department, Hôpital Pitié-Salpêtrière, 83 Bd de l ’Hôpital, F-75013, Paris, France. E-mail: david.klatzmann{at}sorbonne-universite.fr. Phone: +33 1 42 17 74 61
Posted July 19, 2024.
Low-dose interleukin-2 in patients with bipolar depression: a phase 2 randomised double-blind placebo-controlled trial
